Telix Taps Cardinal Health for US Distribution of Kidney Cancer PET Agent

Telix Pharmaceuticals Limited announced that it has selected Cardinal Health, Inc. as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET agent, Zircaix (TLX250-CDx), for the imaging of kidney cancer in the US, subject to regulatory approval.

In preparation for a planned commercial rollout, Telix has contracted with Cardinal Health to enable Zircaix availability across a wide range of US locations.

Kevin Richardson, Chief Executive Oficer, Telix Precision Medicine said, "We are pleased to build on our existing relationship with Cardinal Health to maximize patient access to this breakthrough product for non-invasive kidney cancer diagnosis. Through their extensive nuclear pharmacy network, which enables broad geographic reach and flexible scheduling, Cardinal Health has been central to the commercial success of Illuccix PSMA-PET imaging and we look forward to adding Zircaix to their US roster."

Mike Pintek, President of Cardinal Health Nuclear & Precision Health Solutions, added, "This new agreement builds upon our successful relationship with Telix and our continued commitment to supporting innovative diagnostics and therapeutics addressing cancer patients today. Pending regulatory approval, our extensive commercial distribution infrastructure and expertise will facilitate reliable supply of Zircaix throughout the US to help diagnose kidney cancer."

Commencement of the distribution agreement between Telix and Cardinal Health is subject to regulatory approval and includes industry-standard commercial performance and termination conditions.